New Retina Radio
New Retina Radio

02.22.24

The State of Biosimilars: How We Got Here and What It Means for Practice

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?  Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.  This podcast is editorially independent, supported with advertising by Sandoz. 

View full description +

MORE EPISODES

12.09.25

DME, DR, and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

12.09.25

Wet AMD and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

12.04.25

Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3)

Jay Sridhar, MD; Durga Borkar, MD, MMCi; and Christina Weng, MD, MBA

12.04.25

Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3)

Jay Sridhar, MD; Maggie Runner, MD; and Veeral Sheth, MD, MBA

12.04.25

Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3)

Jay Sridhar, MD; Danny Mammo, MD; and David Sarraf, MD

11.25.25

Global Discussions in GA: Educating Patients and Encouraging Follow-Up

Anat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD

11.25.25

Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring

Anat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD

11.21.25

Endophthalmitis Rates With and Without Antibiotic Prophylaxis

Sruthi Arepalli, MD; Jesse Sengillo, MD; and Alexis Warren, MD

Show More